Geode Capital Management LLC Cuts Stake in Hookipa Pharma Inc (NASDAQ:HOOK)

Geode Capital Management LLC lessened its stake in shares of Hookipa Pharma Inc (NASDAQ:HOOK) by 89.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 72,679 shares of the company’s stock after selling 635,149 shares during the quarter. Geode Capital Management LLC owned about 0.60% of Hookipa Pharma worth $313,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Renaissance Technologies LLC raised its stake in Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after acquiring an additional 83,800 shares during the period. Ikarian Capital LLC purchased a new position in Hookipa Pharma during the third quarter worth $228,000. Finally, Acadian Asset Management LLC lifted its position in shares of Hookipa Pharma by 12.3% during the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after purchasing an additional 108,844 shares during the last quarter. Institutional investors own 63.88% of the company’s stock.

Hookipa Pharma Trading Down 17.2 %

Shares of NASDAQ:HOOK opened at $1.78 on Tuesday. The company has a market capitalization of $21.46 million, a PE ratio of -0.48 and a beta of 0.71. The business has a 50 day moving average of $2.44 and a two-hundred day moving average of $4.05. Hookipa Pharma Inc has a 12-month low of $1.75 and a 12-month high of $10.50.

Wall Street Analysts Forecast Growth

HOOK has been the subject of several research analyst reports. HC Wainwright reiterated a “neutral” rating on shares of Hookipa Pharma in a research report on Friday. Royal Bank of Canada lowered Hookipa Pharma from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $48.00 to $2.00 in a research note on Friday, December 20th. Finally, JMP Securities dropped their target price on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 21st.

Hookipa Pharma Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.